Hydrocotarnine is an alkaloid found in the opium poppy (Papaver somniferum). It is a synthetic derivative of the opium alkaloid narcotine. Hydrocotarnine has been shown to exhibit analgesic, antitussive, and anti-inflammatory properties. It is also known to possess sedative and hypnotic effects. Research on hydrocotarnine has focused on its potential therapeutic applications in pain management, cough suppression, and inflammatory diseases. The synthesis of hydrocotarnine involves a multi-step process starting from thebaine, another opium alkaloid. The compound's importance stems from its unique pharmacological profile and its potential as a lead compound for the development of novel drugs.'
hydrocotarnine: RN given refers to parent cpd; structure in Merck, 9th ed, #4679 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3646 |
| CHEMBL ID | 1606295 |
| CHEBI ID | 92664 |
| SCHEMBL ID | 680035 |
| MeSH ID | M0082996 |
| Synonym |
|---|
| unii-g22l6jne61 |
| 4-27-00-06395 (beilstein handbook reference) |
| g22l6jne61 , |
| BRD-K37447567-001-01-8 |
| BRD-K37447567-004-05-3 |
| hydrocotarnine |
| 1,3-dioxolo[4,5-g]isoquinoline, 5,6,7,8-tetrahydro-4-methoxy-6-methyl- |
| DIVK1C_007025 |
| SDCCGMLS-0066725.P001 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro-1,3-dioxolo(4,5-g)isoquinoline |
| 1,3-dioxolo(4,5-g)isoquinoline, 5,6,7,8-tetrahydro-4-methoxy-6-methyl- |
| 5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinoline |
| brn 0017283 |
| einecs 208-978-2 |
| SPECTRUM_000366 |
| SPECTRUM4_001851 |
| SPECTRUM5_000382 |
| cas-5985-00-2 |
| NCGC00016666-01 |
| PRESTWICK3_000605 |
| BSPBIO_000510 |
| BSPBIO_002504 |
| AB00053339 |
| KBIO1_001969 |
| KBIO2_000846 |
| KBIO2_005982 |
| KBIOSS_000846 |
| KBIO2_003414 |
| KBIOGR_002283 |
| KBIO3_002386 |
| PRESTWICK0_000605 |
| PRESTWICK1_000605 |
| SPECTRUM2_001393 |
| SPECPLUS_000929 |
| SPBIO_001406 |
| SPBIO_002729 |
| SPECTRUM3_001433 |
| BSPBIO_003166 |
| BPBIO1_000562 |
| PRESTWICK2_000605 |
| NCGC00016666-04 |
| NCGC00016666-03 |
| NCGC00016666-02 |
| AKOS005068108 |
| 4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinoline |
| STK802005 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline |
| 550-10-7 |
| CHEMBL1606295 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline |
| 8-methoxy-5,6-methylenedioxy-2-methyl-1,2,3,4-tetrahydroisoquinoline |
| hydrocotarnine [who-dd] |
| hydrocotarnine [mi] |
| SCHEMBL680035 |
| BBL029075 |
| 8-methoxy-2-methyl-6,7-methylenedioxy-1,2,3,4-tetrahydroisoquinoline |
| hydrocotarnin |
| DTXSID60203535 |
| 4-methoxy-6-methyl-2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinoline |
| CHEBI:92664 |
| EN300-186673 |
| hydrocotarnine hydrochloride (jp15) |
| 1,2,3,4-tetrahydro-8-methoxy-2-methyl-6,7-methylenedioxyisoquinoline |
| 1,2,3,4-tetrahydro-8-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinoline, 9ci |
| Q27164371 |
| CS-0237743 |
| VS-09097 |
| mfcd00868501 |
| HY-W176629 |
| 4-methoxy-6-methyl-5,6,7,8-tetrahydro-2h-[1,3]dioxolo[4,5-g]isoquinoline |
| Z1824565757 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Hydrocotarnine also did not cause a significant change in the ATPase activity of human P-gp membranes, suggesting that it is not an inhibitor of P-gp." | ( Effect of hydrocotarnine on cytochrome P450 and P-glycoprotein. Ikarashi, N; Ito, K; Kubota, Y; Sugiyama, K; Suto, S; Toda, T, 2009) | 1.48 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " We used HPLC-electrochemical detector (ECD) to determine oxycodone and hydrocotarnine serum concentrations, and used the nonlinear least-squares method (MULTI) for calculation of the pharmacokinetic parameters." | ( Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2007) | 0.81 |
| Class | Description |
|---|---|
| isoquinolines | A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 3.9811 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||